Rhythm Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Rhythm Pharmaceuticals
RYTM Stock  USD 59.92  0.02  0.03%   
Rhythm Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Rhythm Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Rhythm Pharmaceuticals financial statements helps investors assess Rhythm Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rhythm Pharmaceuticals' valuation are summarized below:
Gross Profit
21.5 M
Profit Margin
(2.30)
Market Capitalization
3.7 B
Enterprise Value Revenue
30.1198
Revenue
112.5 M
There are over one hundred nineteen available trending fundamental ratios for Rhythm Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to check out Rhythm Pharmaceuticals' recent fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 25th of November 2024, Market Cap is likely to grow to about 2.8 B. Also, Enterprise Value is likely to grow to about 2.7 B

Rhythm Pharmaceuticals Total Revenue

81.3 Million

Check Rhythm Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rhythm Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 11 M or Selling General Administrative of 117 M, as well as many indicators such as Price To Sales Ratio of 32.53, Dividend Yield of 0.0 or PTB Ratio of 16.4. Rhythm financial statements analysis is a perfect complement when working with Rhythm Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Rhythm Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets186.9 M332.7 M150.9 M
Slightly volatile
Other Current Liabilities49.9 M47.5 M12.5 M
Slightly volatile
Total Current Liabilities58 M55.2 M18.7 M
Slightly volatile
Property Plant And Equipment Net2.4 M2.1 M1.7 M
Slightly volatile
Accounts Payable4.4 M4.9 M3.8 M
Slightly volatile
Cash50.8 M60.1 M41.9 M
Slightly volatile
Non Current Assets Total25.7 M24.5 M7.9 M
Slightly volatile
Non Currrent Assets Other16.1 M15.3 M4.4 M
Slightly volatile
Cash And Short Term Investments169.6 M275.8 M136.9 M
Slightly volatile
Common Stock Total Equity36.4 K64.4 K29.9 K
Slightly volatile
Common Stock Shares Outstanding39.3 M57.7 M37.9 M
Pretty Stable
Short Term Investments142.5 M215.8 M97.1 M
Slightly volatile
Liabilities And Stockholders Equity203.9 M332.7 M154.5 M
Slightly volatile
Non Current Liabilities Total113.2 M107.8 M35.9 M
Pretty Stable
Other Current Assets5.8 M8.9 M4.9 M
Slightly volatile
Other Stockholder Equity1.1 B1.1 B373.9 M
Slightly volatile
Total Liabilities171.1 M163 M54.6 M
Slightly volatile
Property Plant And Equipment Gross6.5 M6.2 M2.3 M
Slightly volatile
Total Current Assets178.6 M308.3 M144.3 M
Slightly volatile
Common Stock44.3 K59 K35.6 K
Slightly volatile
Capital Surpluse1.2 B1.1 B419 M
Slightly volatile
Current Deferred Revenue1.2 M1.3 M5.2 M
Slightly volatile
Other Assets20.5 M19.5 M5.5 M
Slightly volatile
Deferred Long Term Liabilities91.5 M87.2 M32.8 M
Slightly volatile
Long Term Investments10.5 M19.2 M7.8 M
Slightly volatile
Short Term Debt1.1 M1.5 M1.9 M
Slightly volatile
Property Plant Equipment2.3 M2.5 M1.5 M
Slightly volatile
Other Liabilities93.2 M88.7 M32.9 M
Slightly volatile
Net Invested Capital244.6 M169.8 M187.7 M
Slightly volatile
Net Working Capital261.4 M253.1 M195.5 M
Slightly volatile
Capital Stock52.6 K59 K40.8 K
Slightly volatile
Short and Long Term Debt Total2 M1.3 M3.1 M
Slightly volatile
Capital Lease Obligations2 M1.3 M3.1 M
Slightly volatile
Long Term Debt Total1.1 M1.2 M1.3 M
Slightly volatile

Rhythm Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M1.8 M637.9 K
Slightly volatile
Selling General Administrative117 M111.5 M35.4 M
Slightly volatile
Other Operating Expenses274.9 M261.8 M95.3 M
Slightly volatile
Research Development141.7 M135 M57.3 M
Slightly volatile
Total Operating Expenses265.1 M252.5 M93.5 M
Slightly volatile
Interest Income13.8 M13.2 M3 M
Slightly volatile
Reconciled Depreciation1.1 M1.8 M628.8 K
Slightly volatile

Rhythm Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow134.4 M128 M44.6 M
Slightly volatile
Depreciation1.8 M1.8 M608.4 K
Slightly volatile
End Period Cash Flow51 M60.4 M42.1 M
Slightly volatile
Sale Purchase Of Stock119.9 M162.7 M86.2 M
Slightly volatile
Change To Netincome24.6 M23.4 M8.8 M
Slightly volatile
Stock Based Compensation34.2 M32.6 M9.9 M
Slightly volatile
Issuance Of Capital Stock112.2 M63 M150.5 M
Slightly volatile
Net Borrowings57.9 M65.1 M70.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.5334.2413134
Slightly volatile
Days Sales Outstanding10470.0839113
Slightly volatile
Stock Based Compensation To Revenue0.40.42045.3875
Slightly volatile
Capex To Depreciation0.02540.02674.3524
Slightly volatile
EV To Sales31.8133.4816119
Slightly volatile
Inventory Turnover1.021.07864.5058
Slightly volatile
Days Of Inventory On Hand241338126
Slightly volatile
Payables Turnover2.01.90420.3571
Slightly volatile
Research And Ddevelopement To Revenue1.661.742926.9449
Slightly volatile
Capex To Revenue6.0E-46.0E-41.3905
Slightly volatile
Cash Per Share3.454.78293.7272
Slightly volatile
Days Payables Outstanding1821923.7 K
Slightly volatile
Income Quality0.790.73730.9736
Very volatile
Intangibles To Total Assets0.01490.02110.0151
Slightly volatile
Net Debt To EBITDA0.330.34920.968
Pretty Stable
Current Ratio7.235.58438.7161
Pretty Stable
Receivables Turnover3.225.2083.2767
Slightly volatile
Graham Number10.0214.562711.0159
Slightly volatile
Debt To Equity0.00480.00450.0023
Slightly volatile
Capex Per Share8.0E-48.0E-40.0262
Slightly volatile
Revenue Per Share1.411.34250.2646
Slightly volatile
Interest Debt Per Share0.270.25420.0527
Slightly volatile
Debt To Assets0.00170.00230.0017
Slightly volatile
Operating Cycle317408237
Slightly volatile
Days Of Payables Outstanding1821923.7 K
Slightly volatile
Ebt Per Ebit1.030.99870.9646
Pretty Stable
Total Debt To Capitalization0.00470.00450.0023
Slightly volatile
Debt Equity Ratio0.00480.00450.0023
Slightly volatile
Quick Ratio7.225.4288.7
Pretty Stable
Net Income Per E B T0.781.00310.9542
Pretty Stable
Cash Ratio1.031.08843.2248
Slightly volatile
Days Of Inventory Outstanding241338126
Slightly volatile
Days Of Sales Outstanding10470.0839113
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00031.0192
Slightly volatile
Fixed Asset Turnover38.3136.48826.035
Slightly volatile
Debt Ratio0.00170.00230.0017
Slightly volatile
Price Sales Ratio32.5334.2413134
Slightly volatile
Asset Turnover0.240.23270.0433
Slightly volatile
Gross Profit Margin0.70.87990.814
Very volatile

Rhythm Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.8 B2.7 B932.6 M
Slightly volatile
Enterprise Value2.7 B2.6 B877.8 M
Slightly volatile

Rhythm Fundamental Market Drivers

Cash And Short Term Investments275.8 M

Rhythm Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rhythm Pharmaceuticals Financial Statements

Rhythm Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Rhythm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.2 M
Total Revenue77.4 M81.3 M
Cost Of Revenue9.3 M9.8 M
Stock Based Compensation To Revenue 0.42  0.40 
Research And Ddevelopement To Revenue 1.74  1.66 
Revenue Per Share 1.34  1.41 
Ebit Per Revenue(2.38)(2.50)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:
How To Invest In Rhythm
Details
Is Rhythm Stock a good investment?
Details
What is Rhythm Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Rhythm Pharmaceuticals Correlation against competitors.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.32)
Revenue Per Share
1.863
Quarterly Revenue Growth
0.478
Return On Assets
(0.46)
Return On Equity
(1.48)
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY